Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06337188 · ClinicalTrials.gov registry record · NA
Adaptive and Individualized AAC Phase II
A NA study of Communication Disorders, sponsored by Altec.
- Recruiting
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06337188: Recruiting NA study of Communication Disorders, sponsored by Altec.
NCT06337188 is a NA study of Communication Disorders that is actively recruiting participants, run by Altec. The registered enrollment target is 20 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06337188, a NA study of Communication Disorders, is actively recruiting participants, sponsored by Altec.
- RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall objective of this study is to develop an Augmentative and Alternative Communication (AAC) system that is effective in delivering a person-centric communication device that will provide a versatile access method that can automatically learn and adapt to the user's physical abilities by creating a personalized, comprehensive keyboard interface for communication, not otherwise available to people in need of alternative communication.
Primary Outcome
Measures quantitative ratings on the TSQ-WT scale from a minimum rating of 0 to a maximum rating of 4, where the higher value means a better outcome.
Conditions Studied
Interventions
- DEVICE Experimental AAC
- DEVICE Generic AAC
Study Locations (1)
Nebraska
- University of Nebraska Medical Center - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-12-03 |
| Est. Completion | 2026-03-01 |
| Phase | NA |
What NCT06337188 shows while recruiting
NCT06337188 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Communication Disorders appearing as the primary indexed condition, and to 2 interventions - of which Experimental AAC is the first listed.
NCT06337188 reports a single indexed study location in Nebraska.
Frequently Asked Questions
What is clinical trial NCT06337188 about?
NCT06337188 is a clinical study titled "Adaptive and Individualized AAC Phase II". The overall objective of this study is to develop an Augmentative and Alternative Communication (AAC) system that is effective in delivering a person-centric communication device that will provide a versatile access method that can automatically learn and adapt to the user's physical abilities by cr...
What is the current status of trial NCT06337188?
This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2024-12-03. Estimated completion is 2026-03-01.
What conditions does trial NCT06337188 study?
This clinical trial studies the following conditions: Communication Disorders.
What interventions are being tested in trial NCT06337188?
The interventions under investigation include: Experimental AAC (DEVICE), Generic AAC (DEVICE).
Who is sponsoring clinical trial NCT06337188?
This trial is sponsored by Altec, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06337188 being conducted?
This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Communication Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06337188's enrollment target sits among peer trials
20 1768th of 2000 higher than 140 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI